The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-12 2024 | Immunotherapies in the future treatment landscape for Waldenström’s macroglobulinemia
Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the emerging role of immunotherapy in the treatment of Waldenström’s macroglobulinemia. He focuses on the next generation of therapies, such as CAR T-cells and bispecific antibodies, and highlights that these advanced approaches are crucial for achieving deep responses, measurable residual disease (MRD) negativity, and potentially curing the disease. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
AbbVie, Adaptive, Amgen, BMS, GSK, J&J, Legend, Novartis, OncoPep, Pfizer, Takeda, Sebia, Recordati.
